Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tumour cells.
Durvalumab is marketed under the brand name Imfinzi, which is available for intravenous injections. It was granted accelerated approval by the FDA in May 2017 for the treatment of selected patients with locally advanced or metastatic urothelial carcinoma. In September 2018, durvalumab was approved by the EMA for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in ≥ 1% of tumour cells and there was no observable disease progression following platinum-based chemoradiation therapy. On March 27, 2020, durvalumab was approved by the FDA for use in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).
Durvalumab is indicated for the treatment of adults with the following conditions:
Memorial Sloan Kettering Commack, Commack, New York, United States
Memorial Sloan Kettering Nassau, Uniondale, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
M D Anderson Cancer Center, Houston, Texas, United States
Markey Cancer Center, Lexington, Kentucky, United States
Research Site, Taipei City, Taiwan
XCancer/Centeral Care Center, Bolivar, Missouri, United States
Southern Medical Day Care Centre, Wollongong, New South Wales, Australia
Townsville Hospital, Douglas, Queensland, Australia
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
University of Texas Southwestern Medical Center, Dallas, Texas, United States
University of Kansas Cancer Center - Overland Park, Overland Park, Kansas, United States
University of Kansas Cancer Center - North, Kansas City, Missouri, United States
University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.